GleamWall
中文EN

RXRX RECURSION PHARMACEUTICALS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1601830 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY56.2%
TTM net income YoY33.5%
TTM EPS YoY53.3%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR—

Margins

Gross margin29.2%
Operating margin-725.4%
Net margin-697.1%
FCF margin-458.0%
EBITDA margin-617.2%

Returns

ROE-48.7%
ROA-36.3%
ROIC (approx.)-101.8%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets25.9%
Debt / equity0.01x
Current ratio5.01x
Interest coverage-541.56x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$74.68M$58.84M
Cost of revenue$70.95M$45.24M
Gross profit$3.73M$13.60M
R&D expense$475.27M$314.42M
SG&A expense$176.59M$178.18M
Operating income-$648.13M-$479.00M
Interest expense$1.81M$1.57M
Pretax income-$644.89M-$464.79M
Income tax-$136,000-$1.13M
Net income-$644.76M-$463.66M
EBITDA-$564.43M-$442.51M
EPS (basic)-1.44-1.69
EPS (diluted)-1.44-1.69
Weighted avg. shares (diluted)447.45M274.21M
Balance sheet
Cash & equivalents$743.29M$603.02M
Current assets$812.85M$714.27M
PP&E, net$103.93M$141.06M
Goodwill$162.16M$148.87M
Intangibles$309.90M$335.86M
Total assets$1.47B$1.45B
Current liabilities$147.71M$187.47M
Short-term debt$9.09M$8.43M
Long-term debt$9.56M$19.02M
Total debt$18.66M$27.45M
Total liabilities$343.26M$413.82M
Shareholders' equity$1.13B$1.03B
Net debt-$724.64M-$575.58M
Shares outstanding528.18M396.80M
Cash flow statement
Operating cash flow-$371.81M-$359.17M
Capital expenditure$6.47M$13.70M
Free cash flow-$378.28M-$372.87M
Investing cash flow-$16.87M$260.06M
Financing cash flow$521.53M$304.12M
Depreciation & amortization$83.70M$36.49M
Stock-based compensation$111.22M$81.69M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.